EGFR and non-small cell lung carcinoma: In patients with EGFR-mutant NSCLC, those with DLM had worse PFS and OS than those without DLM (DLM vs. non-DLM: PFS: 5.9 vs. 10.6 months, p < 0.001; OS: 11.9 vs. 20.2 months, p < 0.001).